Progyny, Inc.: directors' dealings · United States · SEC (Form 4)

About Progyny, Inc.

Progyny, Inc. (ticker: PGNY) is listed on the U.S. Nasdaq market in the United States. For investors, it is a healthcare benefits company focused on fertility, family-building, and women’s health. The business is not a traditional insurer; instead, Progyny designs benefit solutions and clinical navigation services for employers, health plans, and other benefit purchasers. Its platform combines a curated provider network, care coordination, integrated pharmacy services, and personalized member support, positioning the company as a specialist in a niche but strategically important segment of employee health benefits. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1551306/000155130625000040/pgny-20241231.htm?utm_source=openai)) Progyny was originally incorporated in 2008, changed its name to Progyny, Inc. in 2015, and is headquartered in New York, New York. Its corporate development has been tied to the growth of fertility benefits in the U.S., a category that historically received limited coverage from employers and health plans. Over time, Progyny built a reputation as one of the leading independent specialists in this market, with an emphasis on clinical outcomes, member experience, and streamlined access to reproductive specialists and related services. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001551306/000155130626000020/pgny-20251231.htm?utm_source=openai)) Operationally, the company’s core revenue base centers on fertility benefit services and Progyny Rx, its integrated pharmacy solution. In recent periods, Progyny has also expanded its offering into adjacent areas including maternal health, doula services, men’s health support, and broader women’s health solutions such as menopause and midlife care. This broader product set supports a strategy of becoming a more comprehensive women’s health and family-building platform while remaining anchored in its original fertility-benefits niche. ([investors.progyny.com](https://investors.progyny.com/news-releases/news-release-details/progyny-inc-announces-fourth-quarter-2025-results?utm_source=openai)) From a competitive standpoint, Progyny’s main advantage is specialization. Compared with large diversified insurers and broad employee-benefits platforms, the company differentiates itself through a focused clinical model, a managed provider ecosystem, and proprietary benefit design centered on better care navigation. The company also highlights strong member satisfaction and favorable clinical metrics, which help support its premium positioning with large employers that view reproductive-health benefits as both a talent-retention tool and a strategic HR offering. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1551306/000155130625000040/pgny-20241231.htm?utm_source=openai)) Recent developments have been notable. In 2025, Progyny reported continued revenue growth, while also disclosing that one large client did not renew and that the transition period extended into the first half of the year. By early 2026, the company reported another strong year and launched Progyny Select, described as the industry’s first fully insured supplemental fertility and family-building plan for small U.S. employers. For equity investors, PGNY remains a growth-oriented healthcare services name on Nasdaq, with exposure to U.S. employment trends, employer benefit spending, and ongoing demand for reproductive and women’s health solutions. ([investors.progyny.com](https://investors.progyny.com/news-releases/news-release-details/progyny-inc-announces-fourth-quarter-2025-results?utm_source=openai))